Overview

Clinical Trials to Assess Safety and Efficacy of DWRX2003 Combination With Remdesivir in Moderate to Severe COVID-19 Patients.

Status:
Not yet recruiting
Trial end date:
2022-07-11
Target enrollment:
Participant gender:
Summary
Safety and efficacy of DWRX2003 combination with Remdesivir in moderate to severe COVID-19 patients will be confirmed.
Phase:
Phase 2
Details
Lead Sponsor:
Daewoong Pharmaceutical Co. LTD.